Epithelial membrane protein 3 regulates lung cancer stem cells via the TGF‑β signaling pathway

Kahm,Yeon-Jee; Kim,Rae-Kwon; Jung,Uhee; Kim,In-Gyu

doi:10.3892/ijo.2021.5261

Epithelial membrane protein 3 regulates lung cancer stem cells via the TGF‑β signaling pathway

Authors:
- Yeon-Jee Kahm
- Rae-Kwon Kim
- Uhee Jung
- In-Gyu Kim
View Affiliations

Affiliations: Department of Radiation Biology, Environmental Safety Assessment Research Division, Korea Atomic Energy Research Institute, Daejeon 34057, Republic of Korea
Published online on: September 2, 2021 https://doi.org/10.3892/ijo.2021.5261
Article Number: 80

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Epithelial membrane protein 3 (EMP3) is a transmembrane glycoprotein that contains a peripheral myelin protein 22 domain. EMP3 first received attention as a tumor suppressor, but accumulating evidence has since suggested that it may exhibit a tumor‑promoting function. Nonetheless, the biological function of EMP3 remains largely unclear with regards to its role in cancer. Herein, it was shown that EMP3 expression is upregulated in non‑small cell lung cancer (NSCLC) cells overexpressing aldehyde dehydrogenase 1 (ALDH1). EMP3 was shown to be involved in cell proliferation, the formation of cancer stem cells (CSCs) and in epithelial‑mesenchymal transition (EMT). The ability to resist irradiation, one of the characteristics of CSCs, decreased when the EMP3 mRNA expression was knocked down using small interfering RNA. In addition, when EMP3 knockdown reduced the migratory ability of cells, a characteristic of EMT. Additionally, it was shown that the TGF‑β/Smad signaling axis was a target of EMP3. EMP3 was found to interact with TGF‑β receptor type 2 (TGFBR2) upon TGF‑β stimulation in lung CSCs (LCSC). As a result, binding of EMP3‑TGFBR2 regulates TGF‑β/Smad signaling activation and consequently affects CSCs and EMT. Kaplan‑Meier analysis results confirmed that patients with high expression of EMP3 had poor survival rates. Taken together, these findings showed that EMP3 may be a potential target for management of LCSCs with high expression of ALDH1, and that EMP3 is involved in TGF‑β/Smad signaling activation where it promotes acquisition of cancerous properties in tumors.

View Figures

View References

1	Ben-Porath I and Benvenisty N: Characterization of a tumor-associated gene, a member of a novel family of genes encoding membrane glycoproteins. Gene. 183:69–75. 1996. View Article : Google Scholar : PubMed/NCBI
2	Fumoto S, Hiyama K, Tanimoto K, Noguchi T, Hihara J, Hiyama E, Noguchi T and Nishiyama M: EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma. Cancer Lett. 274:25–32. 2009. View Article : Google Scholar
3	Alaminos M, Dávalos V, Ropero S, Setién F, Paz MF, Herranz M, Fraga MF, Mora J, Cheung NKV, Gerald WL and Esteller M: EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Res. 65:2565–2571. 2005. View Article : Google Scholar : PubMed/NCBI
4	Xue Q, Zhou Y, Wan C, Lv L, Chen B, Cao X, Ju G, Huang Y, Ni R and Mao G: Epithelial membrane protein 3 is frequently shown as promoter methylation and functions as a tumor suppressor gene in non-small cell lung cancer. Exp Mol Pathol. 95:313–318. 2013. View Article : Google Scholar : PubMed/NCBI
5	Jun F, Hong J, Liu Q, Guo Y, Liao Y, Huang J, Wen S and Shen L: Epithelial membrane protein 3 regulates TGF-β signaling activation in CD44-high glioblastoma. Oncotarget. 8:14343–14358. 2017. View Article : Google Scholar
6	Hsieh YH, Hsieh SC, Lee CH, Yang SF, Cheng CW, Tang MJ, Lin CL, Lin CL and Chou RH: Targeting EMP3 suppresses proliferation and invasion of hepatocellular carcinoma cells through inactivation of PI3K/Akt pathway. Oncotarget. 6:34859–34874. 2015. View Article : Google Scholar
7	Hong XC, Fen YJ, Yan GC, Hong H, Yan CH, Bing LW and Zhong YH: Epithelial membrane protein 3 functions as an oncogene and is regulated by microRNA-765 in primary breast carcinoma. Mol Med Rep. 12:6445–6450. 2015. View Article : Google Scholar : PubMed/NCBI
8	Ernst A, Hofmann S, Ahmadi R, Becker N, Korshunov A, Engel F, Hartmann C, Felsberg J, Sabel M, Peterziel H, et al: Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clin Cancer Res. 21:6541–6550. 2009. View Article : Google Scholar
9	Li JJ, Li R, Wang W, Zhang B, Song X, Zhang C, Gao Y, Liao Q, He Y, You S, et al: IDH2 is a novel diagnostic and prognostic serum biomarker for non-small-cell lung cancer. Mol Oncol. 12:602–610. 2018. View Article : Google Scholar : PubMed/NCBI
10	Alidousty C, Baar T, Heydt C, Wagener-Ryczek S, Kron A, Wolf J, Buettner R and Schultheis AM: Advance of theragnosis biomarkers in lung cancer: From clinical to molecular pathology and biology. J Thorac Dis. 11(Suppl 1): S3–S8. 2019. View Article : Google Scholar :
11	Zappa C and Mousa SA: Non-small cell lung cancer: Current treatment and future advances. Transl Lung Cancer Res. 5:288–300. 2016. View Article : Google Scholar :
12	Brognard J, Clark AS, Ni Y and Dennis PA: Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. Cancer Res. 61:3986–3997. 2001.
13	Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
14	Chen SY, Huang YC, Liu SP, Tsai FJ, Shyu WC and Lin SZ: An overview of concepts for cancer stem cells. Cell Transplant. 20:113–120. 2011. View Article : Google Scholar
15	Rycaj K and Tang DG: Cancer stem cells and radioresistance. Int J Radiat Biol. 90:615–621. 2014. View Article : Google Scholar : PubMed/NCBI
16	Suresh R, Ali S, Ahmad A, Philip PA and Sarkar FH: The role of cancer stem cells in recurrent and drug-resistant lung cancer. Adv Exp Med Biol. 890:57–74. 2016. View Article : Google Scholar
17	Zhao W, Luo Y, Li B and Zhang T: Tumorigenic lung tumorospheres exhibit stem-like features with significantly increased expression of CD133 and ABCG2. Mol Med Rep. 14:2598–2606. 2016. View Article : Google Scholar : PubMed/NCBI
18	Okudela K, Woo T, Mitsui H, Tajiri M, Masuda M and Ohashi K: Expression of the potential cancer stem cell markers, CD133, CD44, ALDH1, and β-catenin, in primary lung adenocarcinoma-their prognostic significance. Pathol Int. 62:762–801. 2012. View Article : Google Scholar
19	Marcato P, Dean CA, Pan D, Araslanova R, Gillis M, Joshi M, Helyer L, Pan L, Leidal A, Gujar S, et al: Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells. 29:32–45. 2011. View Article : Google Scholar : PubMed/NCBI
20	Xu SL, Liu S, Cui W, Shi Y, Liu Q, Duan JJ, Yu SC, Zhang X, Cui YH, Kung HF and Bian XW: Aldehyde dehydrogenase 1A1 circumscribes high invasive glioma cells and predicts poor prognosis. Am J Cancer Res. 5:1471–1483. 2015.
21	Vishnubalaji R, Manikandan M, Fahad M, Hamam R, Alfayez M, Kassem M, Aldahmash A and Alajez NM: Molecular profiling of ALDH1⁺ colorectal cancer stem cells reveals preferential activation of MAPK, FAK, and oxidative stress pro-survival signalling pathways. Oncotarget. 9:13551–13564. 2018. View Article : Google Scholar
22	Kim IG, Kim SY, Choi SI, Lee JH, Kim KC and Cho EW: Fibulin-3-mediated inhibition of epithelial-to-mesenchymal transition and self-renewal of ALDH⁺ lung cancer stem cells through IGF1R signaling. Oncogene. 33:3908–3917. 2014. View Article : Google Scholar
23	Buck E, Eyzaguirre A, Barr S, Thompson S, Sennello R, Young D, Iwata KK, Gibson NW, Cagnoni P and Haley JD: Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther. 6:532–541. 2007. View Article : Google Scholar : PubMed/NCBI
24	Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 106:13820–13825. 2009. View Article : Google Scholar : PubMed/NCBI
25	Singh A and Settleman J: EMT, cancer stem cells and drug resistance: An emerging axis of evil in the war on cancer. Oncogene. 29:4741–4751. 2010. View Article : Google Scholar : PubMed/NCBI
26	Du S, Bouquet S, Lo CH, Pellicciotta I, Bolourchi S, Parry R and Barcellos-Hoff MH: Attenuation of the DNA damage response by transforming growth factor-beta inhibitors enhances radiation sensitivity of non-small-cell lung cancer cells in vitro and in vivo. Int J Radiat Oncol Biol Phys. 91:91–99. 2015. View Article : Google Scholar
27	Murai F, Koinuma D, Shinozaki-Ushiku A, Fukayama M, Miyaozono K and Ehata S: EZH2 promotes progression of small cell lung cancer by suppressing the TGF-β-Smad-ASCL1 pathway. Cell Discov. 1:150262015. View Article : Google Scholar
28	Xu J, Lamouille S and Derynck R: TGF-beta-induced epithelial to mesenchymal transition. Cell Res. 19:156–172. 2009. View Article : Google Scholar : PubMed/NCBI
29	Hao Y, Baker D and Dijke PT: TGF-β-mediated epithelial-mesenchymal transition and cancer metastasis. Int J Mol Sci. 20:27672019. View Article : Google Scholar
30	Wang Y and Shang Y: Epigenetic control of epithelial-to-mesenchymal transition and cancer metastasis. Exp Cell Res. 319:160–169. 2013. View Article : Google Scholar
31	Palma Cde S, Grassi ML, Thomé CH, Ferreira GA, Albuquerque D, Pinto MT, Melo FU, Kashima S, Covas DT, Pitteri SJ and Faça VM: Proteomic analysis of epithelial to mesenchymal transition (EMT) reveals cross-talk between SNAIL and HDAC1 proteins in breast cancer cells. Mol Cell Proteomics. 15:906–917. 2016. View Article : Google Scholar : PubMed/NCBI
32	Takahashi K and Yamanaka S: Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 126:663–676. 2006. View Article : Google Scholar
33	Choi SI, Lee JH, Kim RK, Jung U, Kahm YJ, Cho EW and Kim IG: HSPA1L enhances cancer stem cell-like properties by activating IGF1Rβ and regulating β-catenin transcription. Int J Mol Sci. 21:69572020. View Article : Google Scholar
34	Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al: The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 133:704–715. 2008. View Article : Google Scholar : PubMed/NCBI
35	Morel AP, Lièvre M, Thomas C, Hinkal G, Ansieau S and Puisieux A: Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One. 3:e28882008. View Article : Google Scholar
36	Ma Y, Schröder DC, Nenkov M, Rizwan MN, Abubrig M, Sonnemann J, Murrieta-Coxca JM, Morales-Prieto DM, Westermann M, Gassler N and Chen Y: Epithelial membrane protein 2 suppresses non-small cell lung cancer cell growth by inhibition of MAPK pathway. Int J Mol Sci. 22:29442021. View Article : Google Scholar : PubMed/NCBI
37	Blobe GC, Schiemann WP and Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med. 342:1350–1358. 2000. View Article : Google Scholar
38	de Caestecker MP, Piek E and Roberts AB: Role of transforming growth factor-beta signaling in cancer. J Natl Cancer Inst. 92:1388–1402. 2000. View Article : Google Scholar : PubMed/NCBI
39	Yoshinaga K, Obata H, Jurukovski V, Mazzieri R, Chen Y, Zilberberg L, Huso D, Melamed J, Prijatelj P, Todorovic V, et al: Perturbation of transforming growth factor (TGF)-beta1 association with latent TGF-beta binding protein yields inflammation and tumors. Proc Natl Acad Sci USA. 105:18758–18763. 2008. View Article : Google Scholar
40	Korkaya H, Liu S and Wicha MS: Regulation of cancer stem cells by cytokine networks: Attacking cancer's inflammatory roots. Clin Cancer Res. 17:6125–6129. 2011. View Article : Google Scholar : PubMed/NCBI
41	Zhou C, Liu J, Tang Y and Liang X: Inflammation linking EMT and cancer stem cells. Oral Oncol. 48:1068–1075. 2012. View Article : Google Scholar
42	Christians A, Poisel E, Hartmann C, Deimling AV and Pusch S: Characterization of the epithelial membrane protein 3 interaction network reveals a potential functional link to mitogenic signal transduction regulation. Int J Cancer. 145:461–473. 2019. View Article : Google Scholar : PubMed/NCBI
43	Wang YW, Li WM, Wu WJ, Chai CY, Liu HS, Lai MD and Chow NH: Potential significance of EMP3 in patients with upper urinary tract urothelial carcinoma: Crosstalk with ErbB2-PI3K-Akt pathway. J Urol. 192:242–251. 2014. View Article : Google Scholar
44	Lin CY, Lee CH, Chuang YH, Lee JY, Chiu YY, Lee YH, Jong YJ, Hwang JK, Huang SH, Chen LC, et al: Membrane protein-regulated networks across human cancers. Nat Commun. 10:31312019. View Article : Google Scholar :
45	Pasto A, Giordano F, Evangelopoulos M, Amadori A and Tasiotti E: Cell membrane protein functionalization of nanoparticles as a new tumor-targeting strategy. Clin Transl Med. 8:82019. View Article : Google Scholar :
46	Schmit K and Michiels C: TMEM proteins in cancer: A review. Front Pharmacol. 9:13452018. View Article : Google Scholar :